- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | SpyGlass Pharma surges on public debut; AgomAb falls | 4 | Seeking Alpha | ||
| Fr | Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut | 1 | Reuters | ||
| Fr | NASDAQ-Debüt: Aktie von Agomab Therapeutics startet unter Ausgabepreis | 1 | Investing.com Deutsch | ||
| Fr | Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million | 1 | Renaissance Capital | ||
| Fr | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | 1 | FierceBiotech | ||
| Fr | Agomab, SpyGlass Pharma bank a combined $350M in biotech IPOs | 1 | BioPharma Dive | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | 230 | GlobeNewswire (Europe) | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| Di | Agomab Therapeutics NV - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| Mo | AgomAb Therapeutics Prices U.S. IPO At $15-$17 Per ADS | 573 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, said on Monday that it has priced its initial public offering of 12.5 million American... ► Artikel lesen | |
| 29.01. | Belgian biopharma Agomab to raise up to $210M in U.S. IPO | 1 | Seeking Alpha | ||
| 29.01. | Belgian fibrotic disease biotech AgomAb Therapeutics sets terms for $200 million US IPO | 3 | Renaissance Capital | ||
| 29.01. | Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials | 1 | FierceBiotech | ||
| 29.01. | Belgium's Agomab Therapeutics seeks up to $828.5 million valuation in US IPO | 1 | Reuters | ||
| 29.01. | Agomab Therapeutics NV - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 20.01. | Agomab and Spyglass Pharma push the IPO button | 2 | pharmaphorum | ||
| 19.01. | Immunology biotech Agomab, eye-focused SpyGlass Pharma are latest biotechs to share IPO ambitions | 1 | FierceBiotech | ||
| 16.01. | Belgian immunology and inflammatory biotech AgomAb Therapeutics files for a $100 million US IPO | 2 | Renaissance Capital | ||
| 16.01. | Agomab Therapeutics NV - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 10.04.25 | Agomab Therapeutics NV: Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn's to be Presented at Digestive Disease Week 2025 | 293 | Business Wire | Agomab Therapeutics NV ('Agomab') today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor... ► Artikel lesen | |
| 10.03.25 | Agomab Therapeutics NV: Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn's Disease | 316 | Business Wire | -- AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment --
-- Detailed interim STENOVA results to be presented at future scientific conference... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen |
AGOMAB THERAPEUTICS NV ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 14,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.